Session » 5T113 Abstracts: Late-Breaking Abstract Session

Date: Tuesday, October 23, 2018

Time: 4:00PM-6:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

4:00PM-6:00PM: Abstract Number: L18

A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab

4:00PM-6:00PM: Abstract Number: L17

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

4:00PM-6:00PM: Abstract Number: L20

Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee

4:00PM-6:00PM: Abstract Number: L16

Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness

4:00PM-6:00PM: Abstract Number: L15

The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA

4:00PM-6:00PM: Abstract Number: L19

Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].